Court decides to resume sales of Meditoxin Inj.
Court decides to resume sales of Meditoxin Inj.
  • 박효선 기자
  • 승인 2020.05.22 13:59
  • 최종수정 2020.05.22 13:58
  • 댓글 0
이 기사를 공유합니다

This article is translated by AI company Flitto and Infostock Daily using neural machine translation technology.

[Infostock Daily= Reporter Park Hyo-sun] The court ruled that Medytox's main botox product, Meditoxin Inj., will resume sales.

The Daejeon High Court on the 22th decided to suspend the administration of KFDA's temporary suspension of manufacturing and sales of  Meditoxin Inj.

“Medytox could suffer a loss that is difficult to recover, so it is necessary to suspend the disposal of the KFDA” the court said in a written statement.

Medytox will be able to manufacture and sell it again until the decision to cancel Meditoxin Inj. license is made.

The KFDA suspended the provisional manufacturing and sale of  Meditoxin Inj. last month, citing that Meditox used unauthorized raw materials for some items.

The court's ruling is expected to affect the hearing of the KFDA to discuss the cancellation of  Meditoxin Inj.'s license this afternoon.

Reporter Park Hyo-sun

삭제한 댓글은 다시 복구할 수 없습니다.
그래도 삭제하시겠습니까?
댓글 0
계정을 선택하시면 로그인·계정인증을 통해
댓글을 남기실 수 있습니다.